Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis

• Published in: Journal of dermatology 2021-11, Vol.48 (11), p.1652-1664
• Main Authors: Okubo, Yukari, Ohtsuki, Mamitaro, Komine, Mayumi, Imafuku, Shinichi, Kassir, Nastya, Petric, Rosemary, Nemoto, Osamu
• Format: Article
• Language: English
• Subjects: apremilast; Caucasian; Clinical outcomes; Inhibitor drugs; Japan; Original; Pharmacokinetics; Phosphodiesterase; Phosphodiesterase IV; Psoriasis
• ISSN: 0385-2407; 1346-8138
• DOI: 10.1111/1346-8138.16068

Apremilast is an orally available phosphodiesterase 4 inhibitor used for the treatment of moderate to severe psoriasis. The aims of this analysis were to develop a population pharmacokinetic (PPK) model of apremilast based on observed data from phase 1 studies combined with clinical trial data from subjects with moderate to severe psoriasis, and to develop exposure–response (E‐R) models to determine whether Japanese subjects with moderate to severe psoriasis achieve response to apremilast treatment similar to that observed in non‐Japanese, predominantly Caucasian subjects with moderate to severe psoriasis. The PPK model demonstrated that apremilast plasma concentrations and overall apparent clearance rate were comparable between the Japanese and Caucasian subgroups. The E‐R analyses of ≥75% or ≥50% improvement from baseline in Psoriasis Area and Severity Index score and achievement of static Physician Global Assessment score of 0 (clear) or 1 (almost clear) at week 16 indicated that apremilast treatment in Japanese subjects approached the maximal effect with response rates comparable to those in predominantly Caucasian subjects. Overall, the analyses confirm that the approved apremilast 30 mg b.i.d. dose is appropriate for Japanese subjects with moderate to severe psoriasis, with an efficacy profile similar to that previously observed in Caucasian subjects.